TAK — TAKEDA PHARMACEUTICAL CO LTD
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1395064 ·
Last close
$18.19
Market Cap
$58.09B
52W High
$19.10
52W Low
$12.99
ADV30
2,222,939
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,219,900,000,000 | 813,224,000,000 | 201,417,000,000 | 113,197,000,000 | 15,663,271,000,000 | 460,982,000,000 | 8,104,395,000,000 |
| Mar 2026 | 1,094,541,000,000 | 688,837,000,000 | 42,068,000,000 | -368,471,000,000 | 15,511,506,000,000 | 595,054,000,000 | 8,080,857,000,000 |
| Dec 2025 | 1,191,698,000,000 | 790,550,000,000 | 168,822,000,000 | 103,640,000,000 | 15,408,774,000,000 | 654,937,000,000 | 7,764,684,000,000 |
| Sep 2025 | 1,112,796,000,000 | 732,735,000,000 | 68,996,000,000 | -11,802,000,000 | 14,470,300,000,000 | 681,486,000,000 | 7,338,611,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,041,432,000,000
Investing CF
$-369,141,000,000
Financing CF
$-496,819,000,000
CapEx
$-414,659,000,000
Dividends Paid
$-311,901,000,000
Buybacks
$-51,603,000,000
EPS Diluted TTM
$74.39
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$667,007,000,000
Inventory
$1,447,259,000,000
Receivables
$956,140,000,000
ST Investments
$66,600,000,000
EBIT TTM
$-25,457,000,000
Pretax Income TTM
$-130,267,000,000
Interest Exp TTM
$104,810,000,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,618,934,812,672
EBITDA
$1,249,335,967,744
Free Cash Flow
$541,443,883,008
Enterprise Value
$5,134,218,690,560
Total Cash
$460,981,993,472
Total Debt
$5,536,499,105,792
Shares Out
3,193,502,878
Trailing EPS
$-0.34
Book Value
$15.57
ROE
-2.3%
ROA
2.7%
Div Yield
3.38%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 4,505,720,000,000 | 464,451,000,000 | -152,390,000,000 | 15,511,506,000,000 | 8,080,857,000,000 | 7,429,441,000,000 | 1,041,431,000,000 |
| Mar 2025 | 4,581,551,000,000 | 466,370,000,000 | 107,928,000,000 | 14,248,344,000,000 | 7,312,365,000,000 | 6,935,084,000,000 | 1,057,182,000,000 |
| Mar 2024 | 4,263,762,000,000 | 309,901,000,000 | 144,067,000,000 | 15,108,792,000,000 | 7,834,787,000,000 | 7,273,264,000,000 | 716,344,000,000 |
| Mar 2023 | 4,027,478,000,000 | 587,812,000,000 | 317,017,000,000 | 13,957,750,000,000 | 7,603,079,000,000 | 6,354,122,000,000 | 977,156,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.53
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $18.19 · call volume: 420 · put volume: 53
Expected Move to 2027-01-15:
±$2.11
(11.60%) —
implied range
$16.08 –
$20.30
· ATM straddle on $17.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TKPHF | TAKEDA PHARMACEUTICAL CO LTD | $59.08B | $37.00 | — |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $46.15B | $39.60 | — |
| REGN | REGENERON PHARMACEUTICALS, INC. | $76.69B | $758.27 | — |
| ONC | BeOne Medicines Ltd. | $38.16B | $365.94 | — |
| SNYNF | Sanofi | $96.05B | $80.17 | — |
News headlines (Yahoo Finance, 1h cache)
Takeda Pharmaceutical (TSE:4502) Could Be 13% Undervalued On Strong Phase 3 Psoriasis Data
2026-09-30 20:09 · Yahoo
Takeda Reports New Psoriasis Treatment Outperformed Competitor in Phase 3 Trial
2026-09-30 08:12 · Yahoo
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
2026-09-29 12:00 · Yahoo
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
2026-09-22 13:30 · Yahoo
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
2026-09-18 05:00 · Yahoo
Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?
2026-09-17 17:08 · Yahoo
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
2026-09-14 07:00 · Yahoo
Andy Plump, architect of Takeda’s R&D overhaul, to retire next year
2026-09-10 11:24 · Yahoo
Myelodysplastic Syndrome Market Set for Strong Growth During the Forecast Period (2026-2036) as Targeted Therapies and Novel Treatment Approaches Reshape the Landscape | DelveInsight
2026-09-15 14:31 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Monday Trading
2026-09-14 14:39 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.